Groundbreaking G6PD diagnostic test prequalified by WHO to ensure safe malaria treatment

On 18 December 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended treatments to prevent relapse of Plasmodium vivax (P. vivax) infection.

VQW-765 by Vanda Pharmaceuticals for Social Anxiety Disorder (SAD/Social Phobia): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 4, 2023

Kyowa Kirin acquires Orchard Therapeutics for $477.6m

Share this article The deal will enhance Kyowa Kirin’s focus on addressing the unmet medical needs of individuals with genetic and other severe diseases. Credit:

January 25, 2024

Opportunistic atrial fibrillation screening key to preventing strokes

People at risk should be tested for atrial fibrillation every time they attend a health appointment, according to results of the AFFECT-EU project, which is

March 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.